Literature DB >> 15769657

Opioids and the progression of simian AIDS.

Ronald Y Chuang1, Shunji Suzuki, Ted K Chuang, Tomoko Miyagi, Linda F Chuang, Roy H Doi.   

Abstract

This review is a concise description of the study undertaken to examine the modulation by opioids of simian acquired immunodeficiency syndrome (SAIDS) induced by inoculation of rhesus monkeys with simian AIDS virus SIVmac239. The study showed that the replication rate of the virus was several times greater in monkeys made dependent on morphine than in those of non-morphine treated monkeys. Further, a significant change in the mutation rate of the infecting virus in morphine-treated monkeys resulted in the production of mutants that were silent to conventional serological screening tests as well as resistant to AZT. In addition, opioid and chemokine receptors involved were identified in immune cells and a full comparative spectrum of the compromise of the immune system was examined allowing subsequent studies to evaluate wherein the modulation of the development of the syndrome could be better characterized. The data gathered to date are unique and germane to furthering our understanding of AIDS in humans and its subsequent treatment thereof.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769657     DOI: 10.2741/1651

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  22 in total

1.  SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2006-10-24       Impact factor: 3.616

Review 2.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 3.  HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.

Authors:  Kurt F Hauser; Nazira El-Hage; Anne Stiene-Martin; William F Maragos; Avindra Nath; Yuri Persidsky; David J Volsky; Pamela E Knapp
Journal:  J Neurochem       Date:  2006-12-01       Impact factor: 5.372

4.  Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.

Authors:  Farah Ladak; Eugenia Socias; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood; Julio Montaner; M-J Milloy
Journal:  Antivir Ther       Date:  2019

Review 5.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

6.  Lack of correlation between SIV-Nef evolution and rapid disease progression in morphine-dependent nonhuman primate model of AIDS.

Authors:  Richard J Noel; Alia Toro-Bahamonde; Ziomara Marrero-Otero; Suheydi Orsini; Ashish S Verma; Rakesh Kumar; Anil Kumar
Journal:  AIDS Res Hum Retroviruses       Date:  2006-08       Impact factor: 2.205

7.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

Review 8.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

Review 9.  Opiates, immune system, acquired immunodeficiency syndrome, and nonhuman primate model.

Authors:  Richard J Noel; Vanessa Rivera-Amill; Shilpa Buch; Anil Kumar
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

10.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.